Effects of carnitine administration on carotid intima-media thickness and inflammatory factors in patients with polycystic ovary syndrome: A randomized, double-blind, placebo-controlled trial

Talari, H.R. and Azad, Z.J. and Hamidian, Y. and Samimi, M. and Gilasi, H.R. and Afshar, F.E. and Ostadmohammadi, V. and Asemi, Z. (2019) Effects of carnitine administration on carotid intima-media thickness and inflammatory factors in patients with polycystic ovary syndrome: A randomized, double-blind, placebo-controlled trial. International Journal of Preventive Medicine, 10 (1). pp. 1-6.

Full text not available from this repository.
Official URL: https://www.scopus.com/inward/record.uri?eid=2-s2....
DOI: UNSPECIFIED

Abstract

Background: This study was performed to evaluate the effects of carnitine administration on carotid intima-media thickness (CIMT) and inflammatory markers in women with polycystic ovary syndrome (PCOS). Methods: This randomized, double-blind, placebo-controlled trial was conducted among 60 women diagnosed with PCOS according to the Rotterdam criteria, aged 18�40 years. Participants were randomly allocated into two groups to intake either 250 mg/day carnitine (n = 30) or placebo (n = 30) for 12 weeks. High-resolution carotid ultrasonography was conducted at baseline and after the 12-week intervention. Results: After the 12-week intervention, compared with the placebo, carnitine supplementation resulted in a significant decrease in maximum levels of the left CIMT (�0.01 ± 0.02 vs. +0.002 mm ± 0.006 mm, P = 0.001), mean levels of the left CIMT (�0.01 ± 0.02 vs. +0.001 mm ± 0.01 mm, P = 0.001), maximum levels of the right CIMT (�0.01 ± 0.02 vs. +0.006 mm ± 0.01 mm, P < 0.001), and mean levels of the right CIMT (�0.01 ± 0.02 vs. +0.002 mm ± 0.01 mm, P = 0.001). Change in plasma nitric oxide (NO) (+2.4 ± 3.6 vs. +0.2 ± 2.3 μmol/L, P = 0.007) was significantly different between the supplemented patients and placebo group. We did not see any significant effect in serum high sensitivity C-reactive protein (hs-CRP) following the supplementation of carnitine compared with the placebo. Conclusions: Overall, carnitine administration for 12 weeks to participants with PCOS had beneficial effects on CIMT and plasma NO, but did not affect serum hs-CRP levels. © 2019 International Journal of Preventive Medicine.

Item Type: Article
Additional Information: cited By 0
Uncontrolled Keywords: C reactive protein; carnitine; nitric oxide; placebo, adult; arterial wall thickness; Article; clinical assessment; clinical evaluation; comparative study; controlled study; diet supplementation; double blind procedure; drug effect; echography; female; human; inflammation; major clinical study; outcome assessment; ovary polycystic disease; patient compliance; protein blood level; randomized controlled trial; treatment duration
Subjects: Endocrinology Metabolism
Midwifery
Biochemistry, Genetics and Molecular Biology
Divisions: Faculty of Medicine > Basic Sciences > Department of Biochemistry
Depositing User: ART . editor
Date Deposited: 28 Jun 2020 12:43
Last Modified: 28 Jun 2020 12:43
URI: http://eprints.kaums.ac.ir/id/eprint/4684

Actions (login required)

View Item View Item